Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 445

1.

Dynamic changes in N-terminal pro-brain natriuretic peptide in acute coronary syndromes treated with percutaneous coronary intervention: a marker of ischemic burden, reperfusion and outcome.

Buchner S, Debl K, Barlage S, Griese D, Fredersdorf S, Jeron A, Lubnow M, Müller T, Muders F, Holmer S, Riegger GA, Luchner A.

Clin Chem Lab Med. 2010 Jun;48(6):875-81. doi: 10.1515/CCLM.2010.164.

PMID:
20441480
2.

Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline?

Ezekowitz JA, Théroux P, Welsh R, Bata I, Webb J, Armstrong PW.

Can J Physiol Pharmacol. 2007 Jan;85(1):173-8.

PMID:
17487257
3.

Prognostic value of N-terminal-pro-brain natriuretic peptide measurements in patients with acute coronary syndromes.

Ranjith N, Pegoraro RJ, Naidoo DP, Esterhuizen TM.

Cardiovasc J S Afr. 2006 Mar-Apr;17(2):60-6.

4.

Takotsubo cardiomyopathy has a unique cardiac biomarker profile: NT-proBNP/myoglobin and NT-proBNP/troponin T ratios for the differential diagnosis of acute coronary syndromes and stress induced cardiomyopathy.

Fröhlich GM, Schoch B, Schmid F, Keller P, Sudano I, Lüscher TF, Noll G, Ruschitzka F, Enseleit F.

Int J Cardiol. 2012 Feb 9;154(3):328-32. doi: 10.1016/j.ijcard.2011.09.077. Epub 2011 Oct 30.

PMID:
22044675
5.

Plasma N-terminal fragment of the prohormone B-type natriuretic peptide concentrations in relation to time to treatment and Thrombolysis in Myocardial Infarction (TIMI) flow: a substudy of the Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT IV-PCI) trial.

Jarai R, Huber K, Bogaerts K, Droogne W, Ezekowitz J, Granger CB, Sinnaeve PR, Ross AM, Zeymer U, Armstrong PW, Van de Werf FJ; ASSENT IV-PCI investigators.

Am Heart J. 2010 Jan;159(1):131-40. doi: 10.1016/j.ahj.2009.11.001.

PMID:
20102879
6.

N-terminal pro-brain natriuretic peptide and the timing, extent and mortality in ST elevation myocardial infarction.

Ezekowitz JA, Théroux P, Chang W, Mahaffey KW, Granger CB, Weaver WD, Hochman JS, Armstrong PW.

Can J Cardiol. 2006 Apr;22(5):393-7.

7.

A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome.

Dong M, Liao JK, Yan B, Li R, Zhang M, Yu CM.

Int J Cardiol. 2013 Sep 10;167(6):2813-9. doi: 10.1016/j.ijcard.2012.07.007. Epub 2012 Aug 24.

8.

N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction underwent primary percutaneous coronary intervention.

Kwon TG, Bae JH, Jeong MH, Kim YJ, Hur SH, Seong IW, Cho MC, Seung KB, Jang YS, Park SJ; Korea Acute Myocardial Infarction Registry Investigators.

Int J Cardiol. 2009 Apr 3;133(2):173-8. doi: 10.1016/j.ijcard.2007.12.022. Epub 2008 Feb 20.

PMID:
18281115
9.

Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes undergoing left main percutaneous coronary intervention.

Jaberg L, Toggweiler S, Puck M, Frank M, Rufibach K, Lüscher TF, Corti R.

Circ J. 2011;75(11):2648-53. Epub 2011 Sep 3.

10.

Relative role of NT-pro BNP and cardiac troponin T at 96 hours for estimation of infarct size and left ventricular function after acute myocardial infarction.

Steen H, Futterer S, Merten C, Jünger C, Katus HA, Giannitsis E.

J Cardiovasc Magn Reson. 2007;9(5):749-58.

PMID:
17891611
11.
12.

The value of N-terminal proB-type natriuretic peptide for early identification of myocardial infarction in patients with high-risk non-ST-elevation acute coronary syndromes.

Riezebos RK, Laarman GJ, Tijssen JG, Verheugt FW.

Clin Chem Lab Med. 2011 Aug;49(8):1359-65. doi: 10.1515/CCLM.2011.213. Epub 2011 Jun 22.

PMID:
21692686
13.

Additive prognostic value of NT-proBNP over TIMI risk score in intermediate-risk patients with acute coronary syndrome.

Eren NK, Ertaş F, Yüksek U, Cakir C, Nazli C, Köseoğlu M, Ergene O.

Turk Kardiyol Dern Ars. 2009 Jan;37(1):1-8.

14.

NT-proBNP for prognostic and diagnostic evaluation in patients with acute coronary syndromes.

Zdravkovic V, Mladenovic V, Colic M, Bankovic D, Lazic Z, Petrovic M, Simic I, Knezevic S, Pantovic S, Djukic A, Zdravkovic N.

Kardiol Pol. 2013;71(5):472-9. doi: 10.5603/KP.2013.0093.

16.

Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction.

Björklund E, Jernberg T, Johanson P, Venge P, Dellborg M, Wallentin L, Lindahl B; ASSENT-2 and ASSENT-PLUS Study Groups.

Heart. 2006 Jun;92(6):735-40. Epub 2005 Oct 26.

17.

Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome.

Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, Park HS, Cho Y, Chae SC, Jun JE, Park WH.

Circ J. 2006 Nov;70(11):1379-84.

18.

Effect of Coronary Atherosclerosis and Myocardial Ischemia on Plasma Levels of High-Sensitivity Troponin T and NT-proBNP in Patients With Stable Angina.

Caselli C, Prontera C, Liga R, De Graaf MA, Gaemperli O, Lorenzoni V, Ragusa R, Marinelli M, Del Ry S, Rovai D, Giannessi D, Aguade-Bruix S, Clemente A, Bax JJ, Lombardi M, Sicari R, Zamorano J, Scholte AJ, Kaufmann PA, Knuuti J, Underwood SR, Clerico A, Neglia D.

Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):757-64. doi: 10.1161/ATVBAHA.115.306818. Epub 2016 Feb 11.

PMID:
26868212
20.

[N-terminal pro-brain natriuretic peptide (NT-proBNP) and ischemia modified albumin (IMA) in exercise induced ischemia in patients with stable coronary artery disease].

Piechota WN, Wierzbowski R, Piechota WT, Bejm J, Gielerak G.

Pol Arch Med Wewn. 2006 Jul;116(1):640-7. Polish.

PMID:
17340970
Items per page

Supplemental Content

Write to the Help Desk